NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Stock Information for NeuroSense Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroSense Therapeutics Ltd.

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.